Shamburg News · 8-K filed Nov 16, 2026, 4:16 PM EST

BrainStorm Cell Therapeutics Reports Q3 2026 Net Loss of $1.7 Million

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

  • Earnings
  • Materiality: high

BrainStorm Cell Therapeutics reported a net loss of approximately $1.7 million for the third quarter ended September 30, 2026, compared with approximately $2.1 million for the third quarter of 2025. Basic and diluted net loss per share was $(0.14), compared with $(0.19) a year earlier. Cash, cash equivalents, and restricted cash were approximately $0.35 million as of September 30, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-128336.

Written from the filing by Shamburg Markets. Figures are as reported by the company.